Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Technical Presentation (June 2017)

13 slides from Adaptimmune Therapeutics's technical presentation, Jun 6, 2017

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  2. Slide 2: Synovial Sarcoma Overview

    Synovial Sarcoma Rare cancer; ~20% of all soft tissue sarcomas a Peak incidence among people in their 30s Tumors primarily in extremities Near joints and tendons Treatment includes radiotherapy, chemotherapy, and surgery Many patients undergo “radical” treatments including amputations Patients have

  3. Slide 3: Key Study Design Elements

    Key Study Design Elements 4 NY-ESO in synovial sarcoma Design Element Overview Objectives Primary – response rate by RECIST v1.1 Secondary – overall survival, safety, duration of response, progression-free survival Exploratory – persistence, phenotype, and function of SPEAR T-cells; mechanisms of re

  4. Slide 4: Response Summary

    Response Summary 5 Responses observed in every cohort Measure Cohort 1 (closed) N=12 Cohort 2 (ongoing) N=5 Cohort 3 (closed) N=5 Cohort 4 (ongoing) N=6 Best overall response: N (%) CR PR SD PD Not assessed 1 (8) 5 (42) 6 (50) 0 (0) 0 (0) 0 (0) 2 (40) 1 (20) 1 (20) 1 (20) 0 (0) 1 (20) 4 (80) 0 (0) 0

  5. Slide 5: Overview - Kinetics of Response

    6 Overview - Kinetics of Response Percent change from baseline in target lesions Cohort 1 Cohort 2 Cohort 3 Cohort 4 ORR=50%; N=12 Flu/Cy; NY-ESOhi ORR=40%; N=5 Flu/Cy; NY-ESOlow ORR=20%; N=5 Cy only; NY-ESOhi ORR=50%; N=6 Mod. Flu/Cy; NY-ESOhi Data cutoff 30 Mar 2017

  6. Slide 6: Case Study Patient 309

    7 Baseline (lung) Month 6 (lung) Baseline: 15-yr-old female with synovial sarcoma of left calf, bilateral lung metastases Heavily pre-treated; amputation above knee, thoracotomy On-study disease in lungs Post-infusion: 3.02 x 109 transduced cells CRS Day 2-3: Grade 2; resolved Partial response – Wee

  7. Slide 7: Cohort 1 Survival update

    Cohort 1 8 Survival update – median estimated overall survival 120 wks (~28 mos) a 12 treated patients: 5 have >2 years survival 159 wks (~37 mos) b a 95% CI (37, NE); log(-log) median OS b 95% CI (45, NE); log(-log) median OS 10 at target dose: > 109 transduced cells Data cutoff 30 Mar 2017

  8. Slide 8: AEs > Grade 3 in >10% of Patients continue to be well-tolerated

    AEs > Grade 3 in >10% of Patients 9 NY-ESO SPEAR T-cells continue to be well-tolerated Adverse Event a Cohort 1 N=12 (%) Cohort 2 N=5 (%) Cohort 3 N=5 (%) Cohort 4 N=6 (%) Total N=28 (%) White blood cell count decreased 11 (92) 4 (80) 5 (100) 3 (50) 23 (82) Lymphocyte count decreased 12 (100) 4 (80)

  9. Slide 9: Adverse Events of Interest continue to be well-tolerated

    Adverse Events of Interest 10 NY-ESO SPEAR T-cells continue to be well-tolerated CRS Grade 3 or above 14.3% No Grade 5 All cases resolved Neurotoxicity 0 Events of seizure, cerebral edema, or encephalopathy Data cutoff 30 Mar 2017

  10. Slide 10: Maximum Expansion of Non-responders vs. responders

    Maximum Expansion of NY-ESO SPEAR T-cells 11 Non-responders vs. responders Cohort 1 All Patients P=0.0411 P=0.0108 Data cutoff 30 Mar 2017 Wilcoxon Rank Sum Test (Exact)

  11. Slide 11: Conclusions

    Conclusions 12 Data update: NY-ESO in synovial sarcoma Initial efficacy results encouraging Cohort 1 survival data is promising NY-ESO SPEAR T-cells continue to be well-tolerated Maximal expansion appears to correlate with response

  12. Slide 12: NY-ESO in Synovial Sarcoma ASCO Update

    NY-ESO SPEAR T-cells in Synovial Sarcoma June 6, 2017 ASCO Update

  13. Slide 13: NY-ESO in Synovial Sarcoma ASCO Update June 6, 2017

    NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 & Adaptimmune NSFORMING TCE

Adaptimmune Therapeutics — Technical Presentation (June 2017) on 6ix